trending Market Intelligence /marketintelligence/en/news-insights/trending/VYRahSWW1fNOCVNBI3SAfg2 content esgSubNav
In This List

Johnson & Johnson to expand coverage of joints drug

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity

Blog

Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise


Johnson & Johnson to expand coverage of joints drug

Janssen Biotech Inc. sought U.S. FDA approval to expand Simponi Aria's coverage as a treatment for active psoriatic arthritis and active ankylosing spondylitis.

The Johnson & Johnson unit filed two supplemental biologics license applications for the drug, which is already approved as a therapy for adult patients with moderate to severe active rheumatoid arthritis.

Psoriatic arthritis and ankylosing spondylitis affect more than 2 million Americans, Johnson & Johnson noted in a news release.

Arthritis is any disorder that affects joints. Ankylosing spondylitis is a form of arthritis.